南方科技大学知识苑(SUSTech KC): A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC

题名	A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC
作者	Xiao, Lifeng; Kang, Wenyi; Liao, Jiayu; Li, Yuru
通讯作者	Li, Yuru
发表日期	2021-08-01
DOI	10.1007/s00405-021-07033-8
发表期刊	EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY 影响因子和分区
ISSN	0937-4477
EISSN	1434-4726
摘要	Purpose Nasopharyngeal carcinoma (NPC) is a malignant tumor endangering human health. Gemcitabine or cisplatin chemotherapy has been regarded as effective treatment for patients with locoregionally advanced NPC. However, the effect of gemcitabine plus cisplatin concurrent chemoradiotherapy (CCRT) remained controversial among the studies. Therefore, we conducted this meta-analysis to assess the efficacy and safety of induction chemotherapy by gemcitabine and cisplatin (GP regimen) in patients with locoregionally advanced NPC. Methods A systematic literature search was performed using PubMed, Web of Science, and Embase to evaluate the survival benefit and toxicity profiles of patients with locoregionally advanced NPC who were treated with CCRT. A random-effects model or a fixed-effects model was used to pool the data according to the heterogeneity among the included studies. Results A total of five studies with 1286 patients met the inclusion criteria and were included in this meta-analysis. Pooled estimate showed that GP regimen was associated with significant improvements in OS (HR = 0.57, 95% CI 0.45, 0.73; P < 0.001), DFS (HR = 0.56, 95% CI 0.47, 0.66; P < 0.001), and DRFS (HR = 0.51, 95% CI 0.36, 0.73; P < 0.001), but not in LRFS (HR = 0.54, 95% CI 0.25, 1.19; P = 0.126) and ORR (RR = 1.30, 95% CI 0.54, 3.09; P = 0.556). Moreover, the incidence of adverse events of all grades (RR = 1.15, 95%CI 0.11, 1.38; P = 0.063) or grade 3-4 (RR = 0.96, 95%CI 0.57, 1.29; P = 0.385), was comparable between GP regimen and control treatments. Conclusion Our meta-analysis indicated that the patients with locoregionally advanced NPC could benefit from the regimen of gemcitabine plus cisplatin induction chemotherapy.
关键词	Nasopharyngeal carcinoma Gemcitabine plus cisplatin Concurrent chemotherapy Induction chemotherapy Meta-analysis
相关链接	[来源记录]
收录类别	SCI
语种	英语
学校署名	第一 ; 通讯
WOS研究方向	Otorhinolaryngology
WOS类目	Otorhinolaryngology
WOS记录号	WOS:000686448800001
出版者	SPRINGER
ESI学科分类	CLINICAL MEDICINE
来源库	Web of Science
引用统计	被引频次[WOS]：0
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/244952
专题	南方科技大学医院
作者单位	Southern Univ Sci & Technol Hosp, ENT Dept, 6019 Liuxian St,Xili Ave, Shenzhen 518085, Nanshan Distric, Peoples R China
第一作者单位	南方科技大学医院
通讯作者单位	南方科技大学医院
第一作者的第一单位	南方科技大学医院
推荐引用方式 GB/T 7714	Xiao, Lifeng,Kang, Wenyi,Liao, Jiayu,et al. A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC[J]. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY,2021.
APA	Xiao, Lifeng,Kang, Wenyi,Liao, Jiayu,&Li, Yuru.(2021).A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY.
MLA	Xiao, Lifeng,et al."A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC".EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2021).